Form 4: Sana Biotechnology Executive Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Dhavalkumar Dhirajlal Patel, EVP, Chief Scientific Officer of Sana Biotechnology, Inc., reported multiple transactions in common stock on August 26, 2026.

Summary

  • Option exercise/conversion: acquired 125,000 Common Stock on August 26, 2026; holds 224,510 after (Direct).
  • Tax/exercise-price withholding: disposed of 41,158 Common Stock at $4.11 ($169,159) on August 27, 2026; holds 183,352 after (Direct).
  • Option exercise/conversion: disposed of 125,000 Restricted Stock Units on August 26, 2026; holds 250,000 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Dhavalkumar Dhirajlal Patel — Officer (EVP, Chief Scientific Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-08-26Option exercise/conversionCommon Stock125,000——224,510
2026-08-27Tax/exercise-price withholdingCommon Stock41,158$4$169.2K183,352
2026-08-26Option exercise/conversionRestricted Stock Units125,000——250,000

Key Dates

DateDescription
2026-08-26Option exercise/conversion (125,000 shares)
2026-08-27Tax/exercise-price withholding (41,158 shares)
2026-08-26Option exercise/conversion (125,000 shares)

Keywords

insider transaction, Form 4, SANA, Sana Biotechnology, Inc., neutral, Dhavalkumar Dhirajlal Patel

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.